OncoMatch/Clinical Trials/NCT05187338
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Is NCT05187338 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ipilimumab +pembrolizumab +durvalumab for lung cancer.
Treatment: ipilimumab +pembrolizumab +durvalumab — This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Colorectal Cancer
Pancreatic Cancer
Head and Neck Squamous Cell Carcinoma
Breast Carcinoma
Gastric Cancer
Cervical Cancer
Esophageal Carcinoma
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: clinical trial therapy (equipment or drugs)
Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control
Kidney function
Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo-or peritoneal dialysis [excluded]
Liver function
Child-Pugh class A or B/Child score > 7; Albumin > 28 g/L; Total bilirubin < 51 μmol/L
Child-Pugh class A or B/Child score > 7; WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]; Renal failure / insufficiency requiring hemo-or peritoneal dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify